26Jun
26Jun
Xeno Biosciences Starts Phase 1b Proof-of-Concept Study in Obesity
Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today initiation of Phase 1b clinical study which is designed to provide proof-of-concept weight loss results, along with safety and tolerability, using an optimized formulation of the drug candidate XEN-101, in obese adults. The trial is expected to have top line results by the end of the year. The Phase 1b study is a double blinded, randomized, placebo...
18Jun
Dr. Linda Rhodes Joins Akston Biosciences’ Board of Directors
Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, today announced the appointment of Linda Rhodes, VMD, PhD to its Board of Directors. Dr. Rhodes brings Akston thirty years of experience in the animal health industry as a scientist, senior executive, and board member. Dr. Rhodes said, “I enjoy working with early-stage companies that have innovative solutions for animal health unmet needs. Akston combines a track record of inventing pioneering new therapies with the in-house capabilities critical...
15Jun
Xylyx Bio Awarded $2.26M NIH SBIR Grant from National Cancer Institute
Xylyx Bio, Inc., a regenerative medicine company developing groundbreaking solutions for tissue and organ modeling and repair, announced today that it has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Cancer Institute of the National Institutes of Health (NIH) to advance commercial development of its InMatrico® disease modeling and drug testing platform to help scientists discover and test drug candidates for metastatic breast cancer. Xylyx Bio's InMatrico® metastatic breast cancer cell-based assay platform aims to...
04Jun